Pharmacokinetics of Bezafibrate After Single and Multiple Doses in the Presence of Renal Failure

Overview

Journal Klin Wochenschr

Specialty General Medicine

Date 1980 Sep 1

PMID 7442088

Citations 10

Authors

U Abshagen

W Kosters

B Kaufmann

P D Lang

Affiliations

Soon will be listed here.

Citing Articles

Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study.

Ishibashi S, Arai H, Yokote K, Araki E, Watanabe M, Nakanishi M J Atheroscler Thromb. 2024; 32(2):210-225.

PMID: 39231654 PMC: 11802250. DOI: 10.5551/jat.64887.

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.

Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S Int J Mol Sci. 2019; 20(3).

PMID: 30736366 PMC: 6386904. DOI: 10.3390/ijms20030706.

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Miller D, Spence J Clin Pharmacokinet. 1998; 34(2):155-62.

PMID: 9515185 DOI: 10.2165/00003088-199834020-00003.

Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.

Anderson P, Norbeck H Eur J Clin Pharmacol. 1981; 21(3):209-14.

PMID: 7318880 DOI: 10.1007/BF00627922.

Acute muscular syndrome after bezafibrate.

Bock K Klin Wochenschr. 1981; 59(23):1321.

PMID: 7311399 DOI: 10.1007/BF01711183.

References

Abshagen U, Marinow J . Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers. Eur J Clin Pharmacol. 1980; 17(4):305-8. DOI: 10.1007/BF00625805. View

Olsson A, Lang P . Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia. Atherosclerosis. 1978; 31(4):421-8. DOI: 10.1016/0021-9150(78)90137-5. View

Gugler R, Kurten J, Jensen C, Klehr U, Hartlapp J . Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol. 1979; 15(5):341-7. DOI: 10.1007/BF00558438. View

Adam O, Wolfram G, Lang P, Zollner N . [Dose-effects studies with bezafibrate in patients with hypercholesterolemia and hypertriglyceridemia (author's transl)]. MMW Munch Med Wochenschr. 1979; 121(9):319-22. View

Wahl P, Hasslacher C, Lang P, Vollmar J . [Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)]. Dtsch Med Wochenschr. 1978; 103(31):1233-7. DOI: 10.1055/s-0028-1129237. View